Expert Systems, Inc
Expert Systems is a 7-person life sciences accelerator that uses its proprietary Discover Medicines Hybrid AI Platform to incubate and co-develop seed and Series A biotech companies in oncology, neurodegenerative disease, and infectious disease therapeutics.
- Company typePrivate
- Founded2019
- HeadquartersDover, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Expert Systems, Inc does
Expert Systems, Inc. is a privately held Delaware-incorporated life sciences accelerator founded in 2019 that operates the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system covering preclinical drug discovery from target identification through virtual screening, ADMET prediction, chemical liability assessment, and in vitro toxicology. The stack comprises four named proprietary tools: TTRENDS (biotarget search), TargetGraph (knowledge base and KGML models for target-phenotype relationships), DrugInteLLM (LLM-based biomedical data access), and DiscoverNet (SMILES-based ML models for bioactivity and ADMET properties). The company is led by CEO Tudor I. Oprea, MD, PhD, with CTO Alexei Pushechnikov, PhD, CBO Bill Farley, and General Counsel Eddie Rodriguez, JD, supported by a scientific advisory board spanning UCSD, University of Tuebingen, DZNE, and University of Cincinnati.
The business model is accelerator-based rather than traditional SaaS: Expert Systems organizes and manages R&D programs with financial investors and strategic partners, incubates and owns equity stakes in seed and Series A portfolio companies, and earns service fees for drug discovery expertise. Portfolio companies include NeurOdys Therapeutics (Amsterdam, neurodegenerative), Mair Therapeutics (Nijmegen, Parkinson's), Mondego Bio (Cantanhede, PTPN2 immuno-oncology), Polku Therapeutics (Helsinki, neurodegenerative), BIMINI Biotech (Leiden, hematologic cancers), and jointly controlled ventures including Eilean Therapeutics, Lomond Therapeutics, and Trawsfynydd Therapeutics (Traws Pharma). The company reports 30+ R&D programs organized across North America, Europe, and Australia. Distribution is primarily direct accelerator partnerships with biotech/pharma, supplemented by strategic technology integrations such as the December 2025 collaboration with Quantori, which embeds Expert Systems' AI models as Q-Models into Quantori's Q-Scientist platform for enterprise pharma clients. No public pricing is disclosed; engagement is quote-based. The firm has 7 employees (headcount as of available data), with company headquarters registered at 8 The Green, Suite 8390, Dover, Delaware.
Expert Systems, Inc firmographics
Firmographics- Name
- Expert Systems, Inc
- Legal name
- Expert Systems, Inc.
- Website
- https://expertsystems.inc
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Expert Systems is a 7-person life sciences accelerator that uses its proprietary Discover Medicines Hybrid AI Platform to incubate and co-develop seed and Series A biotech companies in oncology, neurodegenerative disease, and infectious disease therapeutics.
- Ownership category
- akta.pro rank
Expert Systems, Inc industry classification
Industry- Product category
- AI-enabled Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Expert Systems, Inc is headquartered
LocationHeadquarters
- HQ city
- Dover
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Expert Systems, Inc business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Accelerator Platform Services: Expert Systems operates as an advanced accelerator platform providing AI-enabled drug discovery services. The company generates revenue by organizing and managing R&D programs for financial investors and strategic partners, establishing seed and Series A companies. Revenue comes from equity stakes in incubated companies and service fees for drug development expertise.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Expert Systems, Inc product offering
Product offeringCore offering
Expert Systems operates a life sciences accelerator that provides AI-enabled drug discovery services through its Discover Medicines Hybrid AI Platform. The company combines proprietary experimental data with artificial intelligence and human expertise to support preclinical drug discovery from target identification through virtual screening, candidate selection, and preparation for first-in-human trials. It organizes and manages R&D programs and establishes seed and Series A biotech ventures in partnership with financial investors and strategic partners.
Product overview
Expert Systems operates a life sciences accelerator offering the Discover Medicines Hybrid AI Platform, an end-to-end Human-AI hybrid system for drug discovery and development. The platform integrates multiple AI-powered tools including TTRENDS for biotarget searching, TargetGraph for knowledge base and target phenotype relationships, DrugInteLLM for LLM-based biomedical data access, and DiscoverNet for SMILES-based ML models for bioactivity and ADMET predictions. The comprehensive suite covers all aspects of preclinical drug discovery from target identification and virtual screening to pharmacokinetics, off-target pharmacology, chemical liability assessment, and in vitro toxicology. The company has established a portfolio of spin-off companies including Mondego Bio (PTPN2 inhibitors for immuno-oncology), NeurOdys Therapeutics (small molecules for neurodegenerative diseases), Mair Therapeutics (TMEM175 modulators for Parkinson's), BIMINI Biotech (WASp modulators for hematological cancers), and Polku Therapeutics (neurodegenerative disease treatments). Expert Systems also supports partner companies including Eilean Therapeutics (eiletoclax, lomonitinib, balamenib), Trawsfynydd Therapeutics (ratutrelvir/TRX01), and Lomond Therapeutics (lonitoclax).
Differentiator
Problem solved
Functional benefit
Brands
- Discover Medicines Hybrid AI Platform: End-to-end Human-AI hybrid platform for drug discovery and development covering preclinical stages from target identification to virtual screening.
- TTRENDS
- TargetGraph
- DrugInteLLM
- DiscoverNet
- Expert Systems Accelerator
Products and services
- Discover Medicines Hybrid AI Platform End-to-end Human-AI hybrid platform covering all aspects of preclinical drug discovery and early development phases, from target identification and virtual screening through non-clinical and clinical pharmacology, chemical liability assessment, and toxicology evaluation. Targeted at pharmaceutical companies and biotech firms requiring AI-enabled preclinical drug discovery services.
- Expert Systems Accelerator Life sciences accelerator service that deploys Expert Systems' hybrid AI/ML technology to cover the entire spectrum of preclinical drug discovery and early development. Supports setup of seed and Series A companies and organizes R&D programs with financial investors and strategic partners across North America, Europe, and Australia.
- TTRENDS Standalone system for searching prospective biotargets, enabling identification and selection of therapeutic targets for drug discovery. Accessible via its own URL.
- DrugInteLLM Standalone suite of LLM-based tools that provides natural language access to biomedical data, databases, and ML models for drug discovery researchers. Accessible via its own URL.
- DiscoverNet Standalone suite of SMILES-based ML models for prediction of bioactivity, off-target effects, subcellular location, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates. Accessible via its own URL.
Quantifiable outcome
- 30+ R&D programs organized and managed across financial investors and strategic partners
- +2 more outcomes
Companies that use Expert Systems, Inc
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Expert Systems, Inc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Expert Systems, Inc partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- QuantoricoreStrategic collaboration to integrate Expert Systems' novel AI models as Q-Models directly into Quantori's Q-Scientist platform. This integration equips pharmaceutical and biotech clients with capabilities to forecast critical outcomes, accelerate candidate selection, and optimize complex drug development workflows, substantially reducing time and cost associated with bringing new medicines to market.
- Rambam AGcoreSwiss-based venture studio and part of Expert Systems accelerator platform. Rambam AG's diversified portfolio of companies and programs is supported by a core group of seasoned industrial experts, key opinion leaders, and dedicated functional experts from Switzerland, Netherlands, Portugal, Germany, and the US.
- Eilean TherapeuticscoreCutting-edge biopharmaceutical company established through collaboration between Orbimed, Torrey Pines Investment, and Dr. John C. Byrd. Harnesses Expert Systems' hybrid AI platform alongside exclusive data, chem-bio platforms, knowledge, and expertise to identify best-in-class and first-in-class small molecule inhibitors for cancer therapy.
- Lomond TherapeuticscoreCollaboration partner for development of lonitoclax, a selective BCL-2 inhibitor. Expert Systems' cutting-edge AI-driven platform has been instrumental in preclinical efforts, speeding up identification and selection of lonitoclax through advanced computational modeling and comprehensive off-target pharmacology evaluations.
- Traws Pharma (Trawsfynydd Therapeutics)coreOngoing collaboration for development of Ratutrelvir (TRX01), a next-generation oral antiviral for COVID-19. Expert Systems' predictive pharmacology and AI-driven molecular modeling played a central role in optimizing pharmacokinetics, safety, and potency profiles without requiring ritonavir co-administration.
- Polku TherapeuticsminorHelsinki-based startup focused on developing treatments for neurodegenerative diseases. Expert Systems provides advanced computational tools and expertise to support Polku's drug discovery efforts in identifying therapeutic targets and optimizing candidate selection.
- i2020 AcceleratorminorAccelerator partner listed on Expert Systems website as part of their partner ecosystem.
- ChemDivminorListed as a partner in Expert Systems' global partner network for drug discovery services.
- ViriomminorListed as a partner in Expert Systems' global partner network, focusing on antiviral and infectious disease therapeutics.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Expert Systems, Inc competitors and assessment
Company assessmentDirect peers
- Insitro: ML-driven drug discovery platform combining induced pluripotent stem cell biology with predictive models for target and candidate discovery in neuroscience, oncology and metabolic disease.
- Schrödinger, Inc. Public computational drug discovery platform (physics-based + ML) covering target ID, virtual screening and ADMET. Closest direct competitor to Expert Systems' Discover Medicines platform with substantially larger scale.
- Atomwise: AI-focused small-molecule discovery company using AtomNet convolutional neural networks for virtual screening and hit optimization, often via pharma partnerships similar to Expert Systems' accelerator model.
- Exscientia (merged with Recursion): AI-driven small-molecule drug design company using generative chemistry and automated design; operates a Centaur AI platform analogous in scope to Expert Systems' Discover Medicines Hybrid AI Platform.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind-derived models (AlphaFold) to pharmaceutical discovery, including pharma partnerships; competing in the same end-to-end AI/ML discovery category.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML for target identification, with an internal and partnered pipeline; comparable in leveraging biomedical data and AI for hypothesis generation.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to advance an internal pipeline and partnerships; comparable in using AI/ML to compress preclinical timelines across multiple therapeutic areas.
- XtalPi: AI + robotics drug discovery platform combining quantum physics, ML and automated lab workflows for small-molecule discovery; directly competitive in AI-enabled lead design and ADMET prediction.
Emerging players
- Iambic Therapeutics: AI-driven small-molecule drug discovery company combining physics-based simulation with neural networks for oncology candidates; comparable in scope but smaller stage with overlapping target prediction use case.
- Cyrus Biotechnology: Computational biology platform offering protein structure prediction (Rosetta-based) and AI protein engineering services to pharma; overlaps with Expert Systems' computational model offerings and protein/biologic discovery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Expert Systems, Inc social profiles
Digital presenceExpert Systems, Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Expert Systems, Inc leadership team
Management profileNumber of profiles
Profiles10 records
Expert Systems, Inc subsidiaries and ownership
Company hierarchySubsidiaries8 records
Expert Systems, Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Expert Systems, Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Expert Systems, Inc
What does Expert Systems, Inc do?
Expert Systems operates a life sciences accelerator that provides AI-enabled drug discovery services through its Discover Medicines Hybrid AI Platform. The company combines proprietary experimental data with artificial intelligence and human expertise to support preclinical drug discovery from target identification through virtual screening, candidate selection, and preparation for first-in-human trials. It organizes and manages R&D programs and establishes seed and Series A biotech ventures in partnership with financial investors and strategic partners.
Is Expert Systems, Inc a public or private company?
Expert Systems, Inc is a private company. It is classified as venture growth investor backed and is currently operating.
When was Expert Systems, Inc founded?
Expert Systems, Inc was founded in 2019. It employs 1 to 10 people.
Where is Expert Systems, Inc based?
Expert Systems, Inc is headquartered in Dover, United States, in the North America region.
How does Expert Systems, Inc make money?
One revenue line is on record: accelerator Platform Services.
Who are Expert Systems, Inc's main competitors?
Direct peers on record are Insitro, Schrödinger, Inc., Atomwise, Exscientia (merged with Recursion), Isomorphic Labs, BenevolentAI, Recursion Pharmaceuticals and XtalPi. Emerging players are Iambic Therapeutics and Cyrus Biotechnology.
Does Expert Systems, Inc have an API?
No public API is recorded for Expert Systems, Inc.
What industry is Expert Systems, Inc in?
Expert Systems, Inc's product category is AI-enabled Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7373.